2-substituted aminobenzothiazole compound and application thereof

By developing 2-substituted aminobenzothiazoles compounds, the shortcomings of existing sEH inhibitors in clinical application and therapeutic effects were solved, and significant sEH inhibitory activity and effective treatment and prevention of various diseases were achieved.

CN119707861AActive Publication Date: 2025-03-28WUHAN HENGXINYUAN PHARMACEUTICAL CO LTD +3
2 Cites 1 Cited by

Patent Information

Application Number
CN202411733786.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-29
Publication Date
2025-03-28
Estimated Expiration
2044-11-29

AI Technical Summary

Technical Problem

Existing sEH inhibitors have not been used in clinical practice and have limited effectiveness in treating a variety of diseases, making it difficult to effectively prevent or treat diseases mediated by sEH.

Method used

A series of 2-substituted aminobenzothiazoles compounds have been developed to verify their significant sEH inhibitory activity by in vitro and in vivo experiments to prepare drugs for the treatment and/or prevention of sEH-mediated disease.

Benefits of technology

These compounds can stabilize the levels of EETs in the body, significantly inhibit carrageenan-induced foot swelling, protect ischemic brain injury, maintain blood sugar homeostasis, relieve neuropathic pain, resist tissue fibrosis, relieve depression, improve dry eye symptoms, etc., and have extensive therapeutic and preventive potential.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a 2-substituted aminobenzothiazole compound and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition containing the compound and application thereof. The 2-substituted aminobenzothiazole compound is a compound as shown in a general formula I and pharmaceutically acceptable salts thereof, wherein substituent groups R1, R2, R3, R4, m, n, X and Y have meanings given in the specification. The invention also relates to application of the compound shown in the general formula I in preparation of drugs for treating and / or preventing sEH-mediated diseases, in particular to application of the compound shown in the general formula I in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, pain, xerophthalmia, diabetes, diabetic complications, diabetes-related diseases, fibrosis diseases, neurological and mental diseases, ulcerative diseases and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art